Brain–Blood Signals in MDD Show Limited Concordance

Key Takeaways:

• A review reports evidence of partial concordance between brain and blood multiomic signals in MDD, with limited overlap with GWAS-identified risk loci.
• Individual gene-level findings are highly variable, but recurring pathway-level themes are observed across studies.
• Heterogeneity remains a major barrier, and the authors highlight cell-type–resolved and region-specific studies as priorities for future research.

A JAMA Psychiatry systematic review, Brain and Blood Biomarkers of Major Depressive Disorder, summarizes an evidence synthesis integrating bulk and single-nucleus omic studies in major depressive disorder (MDD). In the authors’ framing, the central question is whether molecular dysregulation observed in brain tissue is also detectable in blood when findings are aggregated across gene expression and DNA methylation datasets. The report also describes a parallel aim of comparing these molecular signals with loci identified in genome-wide association studies (GWAS). Overall, the review is presented as a cross-tissue, multiomic effort to examine alignment between brain and blood signals within MDD.

In the review's findings, the authors report that across 54 included studies (30 brain, 20 blood, and 4 both), 744 differentially expressed genes were identified as altered in the same direction across brain and blood datasets, based on aggregated overlap across studies. Of these, 43 overlapped with GWAS-identified MDD risk loci. For DNA methylation, 544 differentially methylated genes were reported as directionally concordant across tissues, with 34 overlapping GWAS loci. These overlaps represent partial alignment across datasets and do not establish causal relationships. Taken together, the report describes evidence of cross-tissue concordance alongside limited overlap with genetic risk loci.

The study also emphasizes substantial heterogeneity, noting that individual dysregulated genes varied widely across studies and across brain regions. Despite this variability, the authors report convergence at the level of hub genes and functional pathways. Pathway categories described include developmental, inflammatory, transcriptional, apoptotic, and mitochondrial processes, reflecting recurring themes rather than a single consistent gene set.

Barriers to clinical translation are framed in terms of this heterogeneity and regional variability, and the abstract notes that no clinically validated biomarkers or precision-medicine–based treatments for MDD currently exist. These gaps are linked to challenges in reproducibly mapping molecular findings across tissues and contexts. As next steps, the authors call for cell-type–specific multiomic studies and increased focus on understudied brain regions, emphasizing research directions rather than near-term clinical application.